Loading...

Global media coverage “Pfizer acquires Redvax GmbH, a spin-off from Redbiotec”

We are pleased with the global media coverage of the acquisition of our spin-off company Redvax GmbH by Pfizer Inc.. This transaction provides access to a preclinical human cytomegalovirus (CMV) vaccine candidate, as well as intellectual property and a technology platform related to a second, undisclosed vaccine program.

Coverage of “Pfizer-Redvax deal” by selected media:

Pfizer Inc.

WSJ

MarketWatch

Nasdaq

2018-07-20T16:07:36+00:00January 15th, 2015|In the press|